The Kansas City Community Clinical Oncology Program (KCCOP) has served the citizens of the Kansas City metropolitan area and beyond for more than 25 years. The KCCOP is one of 27 programs in the nation continuously funded as a CCOP since 1983. The program includes a network of community hospitals, physician investigators, and administrative support to provide broad patient access to National Cancer Institute clinical trials in the Kansas City area. For more than two decades, the KCCOP has exceeded the minimum accrual requirements for treatment, prevention, and cancer control trials. The KCCOP is a cooperative effort involving 11 Kansas City area health care organizations and over 50 medical oncologists, radiation oncologists, surgeons, and other specialists. This program is affiliated with major research bases throughout the nation including the Southwest Oncology Group, Radiation Therapy Oncology Group, Gynecologic Oncology Group, National Surgical Adjuvant Breast and Bowel Project, MD Anderson Cancer Center, Cancer &Leukemia Group B, University of Rochester Cancer Center, and the Clinical Trials Support Unit of the National Cancer Institute. Changes in the healthcare and clinical trials environment require commitment and flexibility. The KCCOP has a dedicated and experienced staff, strong leadership, and a collaborative spirit which provide the right balance for changing times. This program monitors trends and implements measures for continuous improvement. The KCCOP balances protecting patients - their safety and health, well-being, and privacy - with providing the broadest possible access through trial activation, minority outreach, physician participation, and a highly responsive and responsible support staff. Recently, the KCCOP has focused on low accruing investigators to provide them with additional resources. Goals are set to increase accrual in the next year to exceed 100 credits for both cancer treatment and prevention trials.
The KCCOP supports the network mission to accelerate development of interventions to prevent and treat cancer by increasing accruals to trials, fostering quality care in the community through adoption of results, and increasing the involvement of minority and underserved patient populations in cancer clinical trials.
|Dhodapkar, Madhav V; Sexton, Rachael; Waheed, Sarah et al. (2014) Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123:78-85|
|Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7|
|Kernstine, Kemp H; Moon, James; Kraut, Michael J et al. (2014) Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg 98:402-10|
|Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33|
|Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8|
|Deininger, Michael W; Kopecky, Kenneth J; Radich, Jerald P et al. (2014) Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 164:223-32|
|Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5|
|Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42|
|Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7|
|El-Khoueiry, A B; Rankin, C; Siegel, A B et al. (2014) S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 110:882-7|
Showing the most recent 10 out of 126 publications